

## AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended): A method for the ~~treatment or~~ prevention of Alzheimer's disease, in a human, comprising administering to ~~[[a]]~~ the human in need thereof an effective amount of an agent ~~which results in lowered serum insulin levels~~ selected from at least one member of the group of troglitazone, ciglitazone, pioglitazone, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, and englitazone.
2. (currently amended): ~~The method of claim 1, wherein said agent is~~ A method for the prevention of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of chromium.

Claims 3-6 (cancelled)

7. (currently amended): The method of claim [6] 21, wherein said thiazolidinedione is troglitazone.
8. (currently amended): A method for the ~~treatment or~~ prevention of Alzheimer's disease, in a human, comprising restricting the metabolizable carbohydrates in the diet of the human to a level which results in lowered serum insulin levels.
9. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 55 grams per day.
10. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 30 grams per day.
11. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 15 grams per day.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

12. (original): The method of claim 8, wherein the metabolizable carbohydrates in the diet are limited to no more than about 10 grams per day.

13. (currently amended): A method for the ~~treatment or~~ prevention of Alzheimer's disease, in a human, comprising administering to ~~[[a]]~~ the human in need thereof an effective amount of an agent which ~~results in lowered serum insulin levels~~ increases the insulin sensitivity of the human and restricting the metabolizable carbohydrates in the diet of the human.

14. (original): The method of claim 13, wherein said agent is selected from the group consisting of chromium, insulin-like growth factor, a dopamine agonist and a thiazolidinedione.

15. (original): The method of claim 13, wherein said agent is troglitazone.

16. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 55 grams per day.

17. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 30 grams per day.

18. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 15 grams per day.

19. (original): The method of claim 13, wherein the metabolizable carbohydrates in the diet are limited to no more than about 10 grams per day.

Claim 20 (cancelled)

21. (new) A method for the prevention of Alzheimer's disease, in a human, comprising administering to the human in need thereof an effective amount of a thiazolidinedione selected from at least one member of the group of troglitazone, ciglitazone, pioglitazone, 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione, englitazone, and the pharmaceutically acceptable salts thereof.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

22. (new): The method of claim 21, wherein said thiazolidinedione is pioglitazone.
23. (new): The method of claim 21, wherein said thiazolidinedione is pioglitazone hydrochloride.
24. (new): The method of claim 21, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione.
25. (new): The method of claim 21, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate.
26. (new): The method of claim 21, wherein said thiazolidinedione is pioglitazone or a pharmaceutically acceptable salt thereof.
27. (new): The method of claim 21, wherein said thiazolidinedione is 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione or a pharmaceutically acceptable salt thereof.
28. (new): The method of claim 21, wherein said thiazolidinedione is troglitazone or a pharmaceutically acceptable salt thereof.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com